FMP
Kezar Life Sciences, Inc.
KZR
NASDAQ
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
6.38 USD
-0.14 (-2.19%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Christopher J. Kirk Ph.D.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. ...
CIK
0001645666
ISIN
US49372L1008
CUSIP
49372L100
Address
4000 Shoreline Court
Phone
650 822 5600
Country
US
Employee
58
IPO Date
Jun 21, 2018
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
KZR Financial Summary
CIK
0001645666
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
49372L100
ISIN
US49372L1008
Country
US
Price
6.38
Beta
0.22
Volume Avg.
107.37k
Market Cap
46.55M
Shares
-
52-Week
5.2-11.4
DCF
1.64
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.49
P/B
-
Website
https://www.kezarlifesciences.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest KZR News
It looks like there's no news available.
